Breast cancer is one of the most diagnosed cancers among women, with an estimated 2.1 million new cases of breast cancer globally each year. Immunotherapy for breast cancer is developing rapidly following the first FDA-approved checkpoint inhibitor for triple-negative breast cancer in March 2019. New treatment regimens combining immunotherapy with chemotherapy, radiation, or surgery are showing promise in clinical trials. Dr. Elizabeth Mittendorf of Dana-Farber/Harvard Cancer Center will answer your questions and discuss current immunotherapy research for breast cancer.
27 ноя 2022
